Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.

Can you name populations in sapropterin trials?

See the DrugPatentWatch profile for sapropterin

Which patient populations were included in sapropterin clinical trials?

Sapropterin (a synthetic form of tetrahydrobiopterin, BH4) was studied in patient populations where BH4 deficiency or BH4 responsiveness is clinically relevant, most notably:

- People with phenylketonuria (PKU) or “hyperphenylalaninemia” whose blood phenylalanine levels respond to BH4 therapy (often described clinically as “BH4-responsive”).
- Pediatric and adult subgroups within those disorders, since PKU and hyperphenylalaninemia occur across ages and sapropterin trials commonly stratify enrollment by age group.

What does “population” mean in the sapropterin trial context (responsive vs. general PKU)?

In practice, “populations” in sapropterin studies usually refers to eligibility based on biochemical phenotype and treatment responsiveness, not just demographics. Trials typically separate:

- BH4-responsive participants (who show a phenylalanine reduction with sapropterin during screening or early treatment)
- Broader PKU/hyperphenylalaninemia populations where the key distinction is whether response is expected or proven

Are there other populations besides PKU/hyperphenylalaninemia in sapropterin trials?

Across clinical development, sapropterin’s primary labeled and trial focus has been PKU and related hyperphenylalaninemia states that are linked to BH4 biology. If you mean a specific trial (by NCT number or publication), tell me which one and I can list the exact inclusion groups used in that study.

What I need from you to name the populations precisely

The wording “sapropterin trials” can point to multiple studies with different inclusion criteria. If you share one of the following, I can answer with the exact populations from that trial:

- Trial identifier (NCT number)
- Indication (classic PKU vs. mild hyperphenylalaninemia, etc.)
- Age range you care about (pediatric vs. adult)

Sources

I don’t have enough provided information here to name specific sapropterin trial populations accurately. If you paste the trial text/paragraph you’re working from (or the NCT number), I’ll extract and list the populations exactly as stated.



Other Questions About Sapropterin :

Can sapropterin's effects on biomarkers be immediate? How was sapropterin's role in the body identified? Can you list biomarkers for sapropterin non response? Which disorder does sapropterin primarily treat? How does sapropterin's production affect air quality? What studies back sapropterin's impact on long term cognitive function? How does sapropterin's independence affect diagnosis?